Why is Atara Biotherapeutics facing a securities class action lawsuit?

Investors allege Atara made misleading statements about manufacturing readiness and clinical data supporting FDA approval of its drug tabelecleucel.

What is tabelecleucel and why is it important to Atara?

Tabelecleucel is a key drug candidate for Atara, and its approval is central to the company’s future revenue and valuation.

What manufacturing problems are alleged in the Atara lawsuit?

The complaint claims Atara had manufacturing deficiencies that could hinder regulatory approval and product consistency.

What is the ALLELE study mentioned in the Atara case?

The ALLELE study is a clinical trial supporting tabelecleucel’s approval, and investors allege it had design or data issues.

Why are clinical trial deficiencies important to investors?

Trial flaws can undermine the credibility of results and reduce the likelihood of FDA approval.

What are investors alleging about Atara’s FDA approval prospects?

Plaintiffs claim the company overstated the likelihood of approval despite known manufacturing and study-related risks.

How could regulatory scrutiny affect Atara’s business?

Increased scrutiny can delay approvals, require additional studies, and raise development costs.

What are investors claiming Atara failed to disclose?

The lawsuit alleges Atara did not fully disclose risks tied to manufacturing issues and clinical study limitations.

How can drug approval setbacks impact Atara’s stock price?

Negative regulatory developments can reduce future revenue expectations and lead to stock declines.

Who may qualify to participate in the Atara class action?

Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Atara lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by May 22, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which alleged misleading statements were made and investors may have purchased shares.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor chosen by the court to represent all class members and oversee the litigation.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting their trades to receive a share of the settlement fund.

Atara Biotherapeutics, Inc. - Faruqi & Faruqi LLP

Atara Biotherapeutics, Inc.

Join Action

Case Details

Ticker ATRA

Class Period 05/20/2024 - 01/09/2026

Lead Plaintiff Deadline 05/22/2026

Days Left to Seek Plaintiff

If you are an Atara Biotherapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Atara between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (2) accordingly, tabelecleucel’s regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara’s business and financial condition; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Lead Plaintiff Deadline: May 22, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Atara Biotherapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify